Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial
Dubee et al.,
Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial,
Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.03.005 (date from earlier preprint), NCT04325893
Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality.
mortality at 28 days relative risk RR 0.54 [0.21-1.42]
combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]
If not stopped early and the same trend continued, statistical significance would be reached on 28 day mortality after ~550 patients (1,300 patients were planned).
Mortality results are not provided for subgroups. For the subgroups receiving AZ:
No safety concerns were identified. This study has been presented as negative, however the results do not support that conclusion.
NCT04325893 (history)
risk of death at day 28, 46.0% lower, RR 0.54, p = 0.21, treatment 6 of 124 (4.8%), control 11 of 123 (8.9%), NNT 24.
|
risk of combined intubation/death at day 28, 26.0% lower, RR 0.74, p = 0.48, treatment 9 of 124 (7.3%), control 12 of 123 (9.8%), NNT 40.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Dubee et al., 21 Oct 2020, Randomized Controlled Trial, France, peer-reviewed, median age 77.0, 18 authors, average treatment delay 5.0 days, trial
NCT04325893 (history).
Abstract: Clinical Microbiology and Infection 27 (2021) 1124e1130
Contents lists available at ScienceDirect
Clinical Microbiology and Infection
journal homepage: www.clinicalmicrobiologyandinfection.com
Original article
Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a
placebo-controlled double blind trial
e 1, 2, *, x, Pierre-Marie Roy 3, 4, x, Bruno Vielle 5, Elsa Parot-Schinkel 5,
Vincent Dube
Odile Blanchet 6, Astrid Darsonval 7, Caroline Lefeuvre 8, Chadi Abbara 9,
Sophie Boucher 4, 10, Edouard Devaud 11, Olivier Robineau 12, Patrick Rispal 13,
Thomas Guimard 14, Emma d’Anglejean 15, Sylvain Diamantis 16, Marc-Antoine Custaud 4, 17,
Isabelle Pellier 18, Alain Mercat 19, for the HYCOVID study groupy
1)
Service des Maladies Infectieuses et Tropicales, CHU d’Angers, Angers, France
CRCINA, Inserm, Universit
e de Nantes, Universit
e d’Angers, Angers, France
3)
Emergency Department, CHU d’Angers, Angers, France
4)
Institut MitoVasc, UMR CNRS 6215 INSERM 1083, Universit
e d’Angers, Angers, France
5)
Biostatistics and Methodology Department, Maison de La Recherche, CHU d’Angers, Angers, France
6)
Centre de Ressources Biologiques, BB-0033-00038, CHU d’Angers, Angers, France
7)
Service Pharmacie, CHU d’Angers, Angers, France
8)
Departement des Agents Infectieux, Laboratoire de Virologie, CHU Angers, Angers, France
9)
Laboratoire de Pharmacologiedtoxicologie, CHU d’Angers, Angers, France
10)
Service d’ORL et Chirurgie Cervico-faciale, CHU d’Angers, Angers, France
11)
Service de M
edecine Interne et Maladies Infectieuses, CH R. Dubos, Pontoise, France
12)
Service Universitaire des Maladies Infectieuses et du Voyageur, CH de Tourcoing, Tourcoing, France
13)
Service de M
edecine Interne, CH Agen, Agen, France
14)
Service de M
edecine Post-urgence, CH D
epartemental de Vend
ee, La Roche sur Yon, France
15)
^pital Andr
Service de M
edecine Interne et Maladies Infectieuses, CH VersaillesdHo
e Mignot, Le Chesnay, France
16)
Service de M
edecine Polyvalente et Maladies Infectieuses, Groupe Hospitalier Sud Ile de France, Melun, France
17)
Centre de Recherche Clinique, CHU d’Angers, Angers, France
18)
Unit
e d'h
ematologie et d'oncologie P
ediatrique, CHU d’Angers, Inserm U1232-CRCINA, Universit
e d’Angers, Angers, France
19)
Departement de M
edecine Intensive-R
eanimation, CHU d’Angers, Universit
e d’Angers, Angers, France
2)
a r t i c l e i n f o
Article history:
Received 10 January 2021
Received in revised form
19 March 2021
Accepted 21 March 2021
Available online 1 April 2021
Editor: L. Leibovici
Keywords:
Coronavirus disease 2019
Hydroxychloroquine
Placebo-controlled
Randomized controlled trial
Severe acute respiratory syndrome
coronavirus 2
a b s t r a c t
Objectives: To determine whether hydroxychloroquine decreases the risk of adverse outcome in patients
with mild to moderate coronavirus disease 2019 (COVID-19) at high risk of worsening.
Methods: We conducted a multicentre randomized double-blind placebo-controlled trial evaluating
hydroxychloroquine in COVID-19 patients with at least one of the following risk factors for worsening:
need for supplemental oxygen, age 75 years, age between 60 and 74 years and presence of at least one
co-morbidity. Severely ill patients requiring oxygen therapy >3 L/min or intensive care were excluded.
Eligible patients were randomized in a 1:1 ratio to receive either 800 mg hydroxychloroquine on day
0 followed by 400 mg per day for 8 days or a placebo. The primary end point..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit